Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
Search Criteria
Gene/CloneSpeciesStageAnatomy ItemExperimenter
myf5xenopus   

Too many results?Too few results?

Experiment details for myf5

Grimaldi A et al. (2004) Assay

Hedgehog regulation of superficial slow muscle fibres in Xenopus and the evolution of tetrapod trunk myogenesis.

Gene Clone Species Stages Anatomy
myf5.L laevis NF stage 28 to NF stage 32 presomitic mesoderm , somite , tail region

Display additional annotations [+]
  Fig. 4. Notochord and Hedgehog signalling are required for normal MRF expression. (A) Notochord was ablated at stage 13 and embryos analysed by in situ hybridisation 2 hours later for XMyf5, XMyoD and actin mRNA. Arrowheads indicate adaxial tissue with high XMyf5 expression that is absent after notochord ablation. (B) Xptc2 expression in stage 28 embryos is ablated by cyclopamine treatment, both in the first wave slow muscle-forming region (arrows) and elsewhere (arrowheads). Solanidine has no effect (inset). (C) Embryos treated with cyclopamine, or ethanol vehicle control, at stage 9 and fixed at stage 28 or 32. XMyf5 in PSM is reduced creating a `gap' in tail expression (arrows). However, dorsal and ventral somite borders retain XMyf5 expression (arrowheads). XMyoD is reduced in tail tip (arrows), but unaffected in somitic stripes anteriorly. The dorsal and ventral somite borders fail to upregulate XMyoD in presence of cyclopamine (white arrows). Note reduced chevron form and dorsoventral extent of anterior XMyoD signal.

Gene Clone Species Stages Anatomy
myf5.L laevis NF stage 35 and 36 mesoderm , somite , tail bud , trunk , dermomyotome

Display additional annotations [+]
  Fig. 7. XMyoD and XMyf5 expression distinguish several myogenic cell populations in Xenopus somites. XMyf5 (A,C,D,G-I) and XMyoD (B,E,F,J) mRNA was detected in whole-mount in situ hybridisation of stage 35 embryos. Sections of stained embryos at the approximate positions shown in A and B were mounted without further treatment (H,J) or after immunohistochemical staining for MyHC (C-G) or PCNA (I). (A,B) Whole-mount embryos showing the distinct expression of XMyf5 and XMyoD, with section positions marked. (C-F) Trunk level sections showing that the superficial (dermomyotome, brackets) layer of the somite has distinct morphology, lacks MyHC expression and expresses XMyf5 in dorsomedial (shown magnified in D) and ventrolateral lips, and in rare cells away from the lips (C, arrows). XMyoD, by contrast, is expressed within the superficial myotome (E,F, arrowheads) and in the most dorsal dermomyotomal cells (E, arrow). (G-I) Tail sections showing that XMyf5 transcript is located medially in undifferentiated posterior tailbud (G). The outer layer of mesoderm lacks XMyf5 (brackets). Cells with less signal appear orientated perpendicular to the notochord in slightly more anterior regions and are most obvious at dorsal and ventral somite extremes (H). The nuclei of some of these XMyf5-expressing cells contain PCNA (I). (J) XMyoD expression is primarily superficial within the somite in tail tip (bracket). (K-M) Col1a1 is expressed in trunk regions at stage 25 (K) and more widely at stage 37 (L), and vibratome sections reveal expression in epidermis and more weakly in underlying dermomyotome (M, arrowheads).